<?xml version="1.0" encoding="UTF-8"?>
<search_results count="10">
  <query>Sovaldi</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT02605798</nct_id>
    <title>A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) &amp; Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Elbanovir</intervention>
      <intervention type="Drug">Sovaldi</intervention>
      <intervention type="Drug">Sovaldi</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genuine Research Center, Egypt</lead_sponsor>
      <collaborator>Multi-Apex Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GRC/1/15/567</other_id>
    </other_ids>
    <first_received>November 12, 2015</first_received>
    <start_date>August 2015</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximal measured plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Time of the maximum plasma concentration (Tmax)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02605798</url>
  </study>
  <study rank="2">
    <nct_id>NCT01054729</nct_id>
    <title>Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Na√Øve GT 1 HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0221</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in Circulating HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054729</url>
  </study>
  <study rank="3">
    <nct_id>NCT01188772</nct_id>
    <title>Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo to match sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>147</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0422</other_id>
    </other_ids>
    <first_received>August 23, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>April 2, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response at the End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) and 24 (SVR24)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 29)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 29)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01188772</url>
  </study>
  <study rank="4">
    <nct_id>NCT02491450</nct_id>
    <title>A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) &amp; Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Heterosofir</intervention>
      <intervention type="Drug">Sovaldi</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genuine Research Center, Egypt</lead_sponsor>
      <collaborator>Pharmed Healthcare, Egypt</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GRC/1/15/562</other_id>
    </other_ids>
    <first_received>June 28, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>July 2, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximal measured plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>(tmax)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02491450</url>
  </study>
  <study rank="5">
    <nct_id>NCT01962441</nct_id>
    <title>Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0153</other_id>
    </other_ids>
    <first_received>October 10, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained viral response 12 weeks after discontinuation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ during treatment</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01962441</url>
  </study>
  <study rank="6">
    <nct_id>NCT02624063</nct_id>
    <title>Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir + Sofosbuvir</intervention>
      <intervention type="Drug">Simeprevir + Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of S√£o Paulo</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TNT</other_id>
    </other_ids>
    <first_received>December 2, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>December 3, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Rapid Virologic Response at Week 4 (RVR)</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment.</outcome_measure>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Relapse at Follow-up Week 12 (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02624063</url>
  </study>
  <study rank="7">
    <nct_id>NCT02021643</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PegIFNŒ±</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>657</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0115</other_id>
    </other_ids>
    <first_received>November 26, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants permanently discontinuing study drug(s) due to an adverse event (AE)</outcome_measure>
      <outcome_measure>Proportion of participants with: HCV RNA &lt; LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02021643</url>
  </study>
  <study rank="8">
    <nct_id>NCT02074514</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0116</other_id>
    </other_ids>
    <first_received>February 26, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 7, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure and viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02074514</url>
  </study>
  <study rank="9">
    <nct_id>NCT02165189</nct_id>
    <title>An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitits C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Scientific Affairs, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104281</other_id>
      <other_id>TMC435HPC2009</other_id>
    </other_ids>
    <first_received>June 10, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GALAXY</acronym>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 12 Weeks of end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 4 Weeks of end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Score at Week 24 (for Arms 1 and 2) and Week 36 (for Arm 3)</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Questionnaire Score at Weeks 4, 8, 12, 16, 20, 24 (for all treatment arms) and Week 36 (for Arm 3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02165189</url>
  </study>
  <study rank="10">
    <nct_id>NCT02206932</nct_id>
    <title>A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV CDC Category A1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir + Simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMC435HPC2008</other_id>
    </other_ids>
    <first_received>July 30, 2014</first_received>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 (HCV RNA &lt;LLOQ, or lower limit of quantification)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02206932</url>
  </study>
</search_results>
